Inovio Pharmaceuticals(US:INO) Globenewswire·2026-03-20 13:00Core Viewpoint - The Gross Law Firm is notifying shareholders of Inovio Pharmaceuticals, Inc. regarding a class action lawsuit due to alleged misleading statements and deficiencies in manufacturing related to the company's CELLECTRA device and its lead product candidate, INO-3107 [1][3]. Group 1: Allegations - The complaint alleges that during the class period from October 10, 2023, to December 26, 2025, Inovio issued materially false and misleading statements [3]. - Specific allegations include deficiencies in manufacturing for Inovio's CELLECTRA device, which impacted the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [3]. - It is claimed that Inovio lacked sufficient information to justify the eligibility of INO-3107 for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [3]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is April 7, 2026, and participation does not require appointment as a lead plaintiff [4]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4]. - The Gross Law Firm emphasizes its commitment to protecting investors' rights and ensuring responsible business practices [5].